InvestorsHub Logo
Post# of 252254
Next 10
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: DewDiligence post# 97407

Friday, 06/18/2010 3:22:53 PM

Friday, June 18, 2010 3:22:53 PM

Post# of 252254
I expect that Gleevec will remain the tyrosine kinase inhibitor of choicee in first-line CML until data from Tasigna and or Sprycel will show superiority in OS.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.